2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01786603 (ClinicalTrials.gov)	November 21, 2013	28/11/2012	Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis (ALS)	Drug: Rasagiline;Drug: Placebo	Richard Barohn, MD	NULL	Completed	21 Years	80 Years	All	80	Phase 2	United States
2	NCT01879241 (ClinicalTrials.gov)	June 2013	12/6/2013	Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis	Efficacy, Safety and Tolerability Study of 1 mg Rasagilinein Patients With Amyotrophic Lateral Scler ...	Amyotrophic Lateral Sclerosis	Drug: Rasagiline;Drug: Placebo	University of Ulm	NULL	Completed	18 Years	N/A	Both	252	Phase 2	Germany
3	EUCTR2011-004482-32-DE (EUCTR)	10/04/2013	21/12/2012	Efficacy, Safety and Tolerability Study of 1 mg Rasagilinein Patients with Amyotrophic Lateral Scler ...	Efficacy, Safety and Tolerability Study of 1 mg Rasagilinein Patients with Amyotrophic Lateral Scler ...	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term ...	Trade Name: AZILECT ® 1 mg Tabletten INN or Proposed INN: Rasagiline Mesilate Other descriptive name: RA ...	Universitätsklinikum Ulm	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Germany
4	NCT01232738 (ClinicalTrials.gov)	December 2011	22/10/2010	Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagilinein Subjects With Amyot ...	Amyotrophic Lateral Sclerosis (ALS)	Drug: rasagiline	Yunxia Wang, MD	Western ALS Study Group	Completed	21 Years	80 Years	All	36	Phase 2	United States;Canada

First Previous1Next Last